100+ Free HKCFP Conjoint MCQ Practice Questions

Explanation: For patients in Group A (stable COPD with infrequent exacerbations and low symptom burden), current guidelines and the Hong Kong Reference Framework recommend initiating maintenance therapy with a single long-acting bronchodilator, which can be either a Long-Acting Muscarinic Antagonist (LAMA) or a Long-Acting Beta2-Agonist (LABA). Short-acting bronchodilators are used as relievers but are not sufficient as sole maintenance therapy. ICS monotherapy is inappropriate for COPD, and LABA/ICS combination is reserved for patients with frequent exacerbations or asthma-COPD overlap.

Explanation: According to the Hong Kong Reference Framework for Common Chronic Diseases in Primary Care, the blood pressure target for patients with diabetes mellitus is less than 130/80 mmHg. Tight blood pressure control in diabetic patients is crucial to reduce the risk of macrovascular and microvascular complications.

Explanation: Metformin is renally cleared and is associated with a risk of lactic acidosis. According to standard clinical guidelines (including HK Reference Framework and RACGP), Metformin is contraindicated in patients with an eGFR < 30 mL/min/1.73m² and should be discontinued. For patients with eGFR between 30-45 mL/min/1.73m², a maximum dose of 1000 mg daily is recommended.

Explanation: For patients with chronic kidney disease (eGFR < 60 mL/min/1.73m² or urine ACR >= 3 mg/mmol) and diabetes, an ACEi or an ARB is the preferred first-line agent for blood pressure management. These agents provide renal protection by causing efferent arteriolar vasodilation, reducing intraglomerular pressure and proteinuria, independent of their systemic blood pressure-lowering effects.

Explanation: GINA guidelines recommend as-needed low-dose inhaled corticosteroid (ICS)-formoterol as the preferred reliever for patients with mild asthma (Track 1). This strategy serves as both reliever and controller, significantly reducing the risk of severe exacerbations compared to SABA-only reliever use. SABA-only treatment is no longer the preferred reliever option due to risks associated with beta-agonist overuse and lack of anti-inflammatory protection.

Explanation: The 'four pillars' of GDMT for HFrEF include an ARNI/ACEi/ARB, a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor (such as Dapagliflozin or Empagliflozin). SGLT2 inhibitors have been shown to significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with HFrEF, regardless of the presence of Type 2 Diabetes. Digoxin and Furosemide improve symptoms but do not reduce mortality, and Amlodipine has no mortality benefit in HFrEF.

Explanation: HLA-B*5801 screening is recommended in Han Chinese populations prior to starting Allopurinol. HLA-B*5801 is strongly associated with the development of Allopurinol-Induced Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). In patients who test positive, alternative agents like Febuxostat should be considered.

Explanation: For osteoarthritis of the knee, topical NSAIDs are recommended as first-line pharmacological therapy over oral NSAIDs due to their localized efficacy and superior safety profile, with minimal systemic absorption. This is especially important for patients with high cardiovascular and gastrointestinal risk, such as this patient. Paracetamol is no longer strongly recommended as first-line therapy due to its marginal efficacy in clinical trials, and oral NSAIDs/opioids carry higher systemic risks.

Explanation: Agranulocytosis is a rare (0.2-0.5%) but life-threatening adverse effect of antithyroid drugs (Carbimazole, Methimazole, Propylthiouracil). Patients must be explicitly instructed to discontinue the drug immediately and seek urgent medical attention for a full blood count if they develop symptoms of infection, such as a sore throat, fever, or mouth ulcers.

Explanation: This patient is in the inactive carrier phase (or HBeAg-negative chronic HBV infection) characterized by normal ALT, low HBV DNA (<2,000 IU/mL), and no significant liver fibrosis. Antiviral treatment is not indicated in this phase. The appropriate management is monitoring ALT and HBV DNA every 3-6 months to detect potential reactivation (ALT elevation and rising HBV DNA). A liver biopsy is unnecessary because transient elastography already confirmed the absence of significant fibrosis.